Clinical Pharmacology &Therapeutics for Adenocarcinoma

Clinical Sciences

Investigators

Abstract

Innovative strategies are needed to improve the prognosis of patients with adenocarcinomas arising in the gastrointestinal tract. We are studying the interaction of modulatory & cytotoxic agents with fluorouracil in vitro to define optimal sequences for potential clinical use. Studies are designed to elucidate the optimal schedule of administration & mechanism of action of novel agents with activity against colon cancer cell lines to facilitate their rational clinical use. We implement clinical trials that incorporate clinical pharmacokinetic, biochemical &/or molecular endpoints. New analytic assay methods are developed to measure the pharmacokinetics & intracellular pharmacodynamics of the anticancer agents. Our goal is to develop new agents & drug combinations for patients with GI cancers, & to develop strategies that selectively target cancer cells with genomic instability &/or impaired programmed cell death pathways.